Novartis AG ADR (NVS)vsInsulet Corporation (PODD)
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
PODD
Insulet Corporation
$131.96
-2.02%
HEALTHCARE · Cap: $9.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1757% more annual revenue ($56.69B vs $3.05B). NVS leads profitability with a 22.5% profit margin vs 12.3%. PODD appears more attractively valued with a PEG of 1.16. PODD earns a higher WallStSmart Score of 71/100 (B).
NVS
Buy51
out of 100
Grade: C-
PODD
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Intrinsic value data unavailable for PODD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Earnings expanding 328.6% YoY
Every $100 of equity generates 23 in profit
Revenue surging 23.5% year-over-year
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Moderate valuation
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : PODD
The strongest argument for PODD centers on EPS Growth, Return on Equity, Revenue Growth. Revenue growth of 23.5% demonstrates continued momentum. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : PODD
The primary concerns for PODD are P/E Ratio.
Key Dynamics to Monitor
NVS profiles as a value stock while PODD is a growth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.08 — expect wider price swings.
PODD is growing revenue faster at 23.5% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
PODD scores higher overall (71/100 vs 51/100) and 23.5% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?